Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BON-C1393 in Advanced Solid Tumors
NCT07904845Phase 1Not yet recruiting
- Sponsor
- BeOne Medicines
- Start
- Nov 2026
- Primary completion
- Feb 2029
01
Overview
Phase 1, open-label trial of BON-C1393 in solid tumor (4 arms), sponsored by BeOne Medicines. Primary endpoints: Dose-Limiting Toxicities at 1 month, Adverse Events at 9 months and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
BON-C1393
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07904845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904845.